Reunion Neuroscience expands Series A to $133m after positive trial milestones
The funding round was boosted by $30m after Reunion’s lead candidate RE104 hit efficacy goals in a Phase II trial.
Therapy Area
aTyr Pharma stock crashes on Phase III pulmonary sarcoidosis fail
Novartis returns to Monte Rosa for second time in a year with $5.7bn deal
Podcast: key trials and trends from ESC Congress 2025
AbbVie extends Rinvoq exclusivity by four years after generics settlements
Sanofi’s Tzield gains approval in China for T1D management
US Government signs $56m smallpox/mpox vaccine order despite political disarray
Novo’s Ozempic price cut expected to slow market share erosion
